Company / SG&A Expense
Bicara Therapeutics Inc. SG&A Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$18.8M
FY2024
5-year range
$9.3M / $18.8M
FY2023-FY2024
Trend
+102.4%
vs FY2023
Sector context
#201 of 213
Health Care
What the data says
Among 213 Health Care companies, Bicara Therapeutics Inc. is in the top 6% for sg&a expense.
Based on SEC 10-K filings.
$19M in FY2024.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 213This company $18.8M Sector average $722.3M
▼
-97.4% below sector average
Key checks
Key Insights
- In FY2024, sg&a expense increased 102.4% year-over-year.
- Ranks #201 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $18.8M | +102.4% |
| FY2023 | $9.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026